Baxter’s Eptifibatide Receives the US FDA’s Approval for Cardiovascular Diseases

 Baxter’s Eptifibatide Receives the US FDA’s Approval for Cardiovascular Diseases

Baxter’s Eptifibatide Receives the US FDA’s Approval for Cardiovascular Diseases

Shots:

  • Baxter’s ready to use Eptifibatide is approved and launched for patients with acute coronary syndrome (ACS) & percutaneous coronary intervention (PCI)
  • The FDA approval strengthens Baxter’s premix portfolio, enhance patient’s safety by avoiding dosing error and reduces the burden on hospital pharmacist
  • Eptifibatide (75mg/100ml) is a platelet aggregation inhibitor, based on Baxter’s galaxy container technology that enhances the shelf life of premixed therapies, currently available in the US

Click here to read full press release/ article | Ref: Baxter| Image: The Baxter Bulletin

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post